Nuvalent Details FDA Timelines for ROS1, ALK Drugs as $1.4B Cash Fuels Global Launch Plans

Nuvalent (NASDAQ:NUVL) executives highlighted ongoing regulatory milestones for the company’s lead oncology programs and ...